Special patient populations: Onychomycosis in the diabetic patient

Journal of the American Academy of Dermatology

Volumn 35, Issue 3 PART II, 1996, Pages

  Rich, Phoebe ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; TERBINAFINE;

BLINDNESS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; HUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UNITED STATES;

DIABETES COMPLICATIONS; HUMANS; ONYCHOMYCOSIS;

EID: 0029763067     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(96)90063-8     Document Type: Article

References (13)

1. Perez M, Kohn S. Cutaneous manifestations of diabetes meffitus. J Am Acad Dermatol 1994;30:519-51.
2. Ratner R. Pathophysiology of the diabetic foot. In: Kominsky S, editor. Medical and surgical management of the diabetic foot. St. Louis: Mosby, 1994:1-6.
3. Hostetter MK. Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes 1990;39:271-5.
4. Wilson RM, Reeves WG. Neutrophil phagocytosis and killing in insulin dependent diabetes. Clin Exp Immunol 1986;63:478-84.
5. Bild DE, Selby JV, Sinnock P, et al. Lower extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care 1989;12:24-31.
6. Lugo-Somolinos A, Sanchez JL. Prevalence of dermatophytosis in patients with diabetes. J Am Acad Dermatol 1992;26:408-10.
7. Alteras I, Saryt E. Prevalence of pathogenic fungi in the webs and toenails of diabetic patients. Mycopathologia 1979;67:157-9.
8. McCarthy DJ, Boyko EJ, Smith DG. Cutaneous manifestations of the lower extremities in diabetes mellitus. In: Kominsky S, editor. Medical and surgical management of the diabetic foot. St. Louis: Mosby, 1994:191-222.
9. Reiber GE, Boyco EJ, Smith DG. Diabetes in America. Washington, DC: National Institutes of Health publication; 1995:409-27.
10. Data on file, Janssen Pharmaceutica (Titusville, NJ).
11. Damanhouri M, Gumbleton M, Nicholis PJ, et al. In-vivo effects of itraconazole on hepatic mixed-function oxidase. J Antimicrob Chemother 1988;21:187-94.
12. Gumbleton M. Tolbutamide pharmacokinetics in the presence of itraconazole in the rat. J Pharm Pharmacol 1987;39(suppl 1):150.
13. Data on file, Pfizer, Inc. (New York, NY).